A Blog from Gerbsman Partners Board of Intellectual Capital on “Maximizing Enterprise Value” for technology, life science, medical device and cleantech companies and their Intellectual Property
Gerbsman Partners is pleased to announce the successful completion of a CEO/Crisis Management assignment for the stabilization of a Private Equity HR Technology Platform Company.
Due to management and potential operational issues, the Board of Directors made the strategic decision to retain Gerbsman Partners to assist in the stabilization of the company.
Gerbsman Partners – led by Steven R. Gerbsman, Principal and Kenneth Hardesty (CEO in Residence)– provided CEO/Crisis Management at the company and Ken Hardesty assumed the role of CEO, at the company in Boston, for a 60 day period. The challenge was that two previous CEO’s resigned from the company due to conflicts with the founder, who was still in an operational mode and there were communications and leadership issues with the employee’s and its main customers. The company was/is very profitable and represented a significant growth opportunity for the Private Equity group and investors.
1. “Hands on, CEO/Crisis Management at the company”.
2. “Stabilized the key employee’s and the Founder, who had resigned”.
3. “ Assisted the Private Equity group in interviewing and hiring a new CEO”.
4. “Identified and stabilized key issues with the company’s primary customer”
5. “Most importantly, met and exceed the business plan for the two month periord”
6. “and Assisted in a smooth transition with the new CEO”
About Gerbsman Partners
Gerbsman Partners focuses on maximizing enterprise value for stakeholders and shareholders in underperforming, undercapitalized and undervalued companies and their intellectual properties. Since 2001, Gerbsman Partners has successfully maximized the values of 122 companies in a wide and diverse spectrum of industries, ranging from technology, medical device/life science, digital marketing to cyber security, to name only a few.*
In the process, GP has successfully restructured/terminated over $810 million of real estate executory contracts and equipment lease/sub-debt obligations, and has assisted in over $2.3 billion of financings, restructurings and M&A transactions.*
Gerbsman Partners has offices and strategic alliances in San Francisco, Orange County, Boston, New York, Washington DC, McLean, VA, Europe and Israel.
*For further information on Gerbsman Partners expertise and industry experience, please request our company profile here
I’m thrilled to share the updated website for my daughter-in-law’s company, http://www.styleauteur.com! It now highlights her work as a keynote speaker, along with a clip of her in action on stage, as well as her coaching and consulting services for companies and organizations.
Her focus is on empowering individuals through personal branding and the power of nonverbal communication – helping leaders and teams show up with confidence, presence, and impact. Whether through a keynote, workshop, or coaching session, Lauren loves working with organizations to elevate how their people present themselves and step into leadership.
I’m also excited to share that she is writing her second book, Style is a Superpower®️, which will focus on empowering readers with the courage to be unstoppable. It’s a natural extension of her work, blending personal style with the mindset and confidence needed to own any room.
If interested, I would recommend for you to take a look at her site, and of course, if any opportunities come to mind where she might be a great fit, I know she would welcome the chance to connect. Please see Lauren’s contact information below
Ron was a dear friend of over 50 years. He passed away this week from Parkinson’s disease.
Ron and I were “Masters of the Universe” in the 1970’s. We were both put in CFO and CEO positions to stabilize, restructure and turnaound a $250 million Data Services Division. Little did we know that this would be our first experiences as Crisis/Turnaround Managers. Ron was a great partner; focused, smart and had high ethics and integrity. We were a very successful team.
Over the years Ron and I worked together many times. He was a Turnaround CEO for a number of Life Science companies, where I worked with him on capital raising and debt financing and after that he began his career as an international Executive Search CEO, where he assisted the private equity and venture capital community.
Ron and his wife Lynn moved to Texas about 15 years ago to raise and jump horses. Although from Chicago, he became a Texan and loved Dallas.
Ron had this great smile – see below.
Ron and I talked once a week and it always put a smile on my face when he called and said “The Gerbs”,
His wife, Lynn, has been a saint taking care of Ron. She put off Chemo to take care of him at home. Lynn our condolences from our family.
Be at peace my friend, you are with “GOD” now.
With respect, with love for a friend and with admiration for the person.
Respectfully – “The Gerbs” and the Gerbsman family.
Successful ‘Date-Certain M&A’ of Stemedica Cell Technologies Inc., its Assets and Intellectual Property
Gerbsman Partners is pleased to announce the successful completion of maximizing the value of the Assets and Intellectual Properties at Stemedica Cell Technologies, Inc.
Due to market conditions and trends, the Board of Directors and senior lender made the strategic decision to maximize the value of its Assets and Intellectual properties.
Gerbsman Partners – led by Steven R. Gerbsman, Principal and Kenneth Hardesty (CEO in Residence)– provided the CEO with financial advisory leadership through its proprietary ‘Date-Certain M&A Process’, facilitated the sale of the company’s Assets and Intellectual Property and the closing of the sale with other company Advisors.
1. Business consulting and investment banking domain expertise in developing strategic action plans.
2. Implementing its proprietary ‘Date-Certain M&A Process’ in order to maximize value of Stemedica Assets and Intellectual properties.
3. “Managing and guiding the process” among potential acquirers, lawyers, advisors, as well as all stakeholders of interest.
About Gerbsman Partners
Gerbsman Partners focuses on maximizing enterprise value for stakeholders and shareholders in underperforming, undercapitalized and undervalued companies and their intellectual properties. Since 2001, Gerbsman Partners has successfully maximized the values of 121 companies in a wide and diverse spectrum of industries, ranging from technology, medical device/life science, digital marketing to cyber security, to name only a few.*
In the process, GP has successfully restructured/terminated over $810 million of real estate executory contracts and equipment lease/sub-debt obligations, and has assisted in over $2.3 billion of financings, restructurings and M&A transactions.*
Gerbsman Partners has offices and strategic alliances in San Francisco, Orange County, Boston, New York, Washington DC, McLean, VA, Europe and Israel.
*For further information on Gerbsman Partners expertise and industry experience, please request our company profile here
of Pennington Biomedical Research Center in Baton Rouge, La. Credit: Pennington Biomedical Research Center
Pennington Biomedical Research Center’s Dr. Steven Heymsfield and Dr. Peter Katzmarzyk are among the most influential researchers in the world who demonstrate significant and broad influence in their fields, according to Clarivate Analytics’ 2024 List of Highly Cited Researchers.
This honor highlights researchers whose work has had significant global influence, as evidenced by their exceptional citation records in leading scientific publications. The 2024 Highly Cited Researchers hail from more than 1,200 institutions in 59 nations and regions.
The Highly Cited Researchers list, compiled annually by Clarivate Analytics, identifies scientists who are among the top 1 percent of researchers in their field, as measured by citations in the Web of Science database during the period from 2013 to 2023.
“Pennington Biomedical is home to all-star researchers known worldwide, and this recognition for Dr. Heymsfield and Dr. Katzmarzyk shows the impact they are having in the field of obesity and nutrition research,” said Dr. John Kirwan, Pennington Biomedical Executive Director. “We congratulate them both for this recognition and all of Louisiana and Baton Rouge can be proud that they are conducting their world-renowned research here at Pennington Biomedical.”
Dr. Heymsfield and Dr. Katzmarzyk are internationally recognized for their groundbreaking contributions to obesity research, physical activity, and public health.
Steven Heymsfield, M.D., Professor of Metabolism & Body Composition, has an h-index of 141. He is listed on 1,314 publications that have been cited close to 80,000 times. His most cited paper, “Epidemiology of sarcopenia among the elderly in New Mexico,” published in the American Journal of Epidemiology, has been cited more than 2,800 times.
“This achievement reflects not just individual recognition, but the incredible support and collaboration of everyone at Pennington Biomedical,” Dr. Heymsfield said. “Conducting impactful and high-quality research requires not only dedication but also access to outstanding facilities, resources, and a thriving scientific community—qualities exemplified at Pennington Biomedical. I am grateful to be part of an institution that fosters innovation and excellence in research, enabling us to address critical challenges in health and nutrition on a global scale.”
Peter Katzmarzyk, Ph.D., Associate Executive Director for Population and Public Health Sciences; Professor; and Marie Edana Corcoran Endowed Chair in Pediatric Obesity and Diabetes, has an h-index of 100. He is listed on 587 publications that have been cited more than 45,000 times. His paper, “Effect of Physical Inactivity on Major Non-Communicable Diseases Worldwide: An Analysis of Burden of Disease and Life Expectancy,” published in Lancet, has been cited more than 5,400 times.
“Being named among the world’s highly cited researchers is both an honor and a reflection of the impact our work is making on global health,” Katzmarzyk said. “This recognition underscores the importance of addressing critical issues like physical inactivity, obesity, and chronic disease to improve lives worldwide.”
The 2024 Highly Cited Researchers list features 3,560 Highly Cited Researcher awards in 20 fields, with an additional 3,326 recognitions for outstanding performance in multiple fields (cross-field).
“The Highly Cited Researchers list identifies and celebrates exceptional individual researchers at Pennington Biomedical whose significant and broad influence in their fields translates to impact in their research community. Their pioneering innovations contribute to a healthier, more sustainable and secure world. These researchers’ achievements strengthen the foundation of excellence and innovation that drives societal progress,” said David Pendlebury, Head of Research Analysis at the Institute for Scientific Information at Clarivate.
About the Pennington Biomedical Research Center
The Pennington Biomedical Research Center is at the forefront of medical discovery as it relates to understanding the triggers of obesity, diabetes, cardiovascular disease, cancer and dementia. Pennington Biomedical has the vision to lead the world in promoting metabolic health and eliminating metabolic disease through scientific discoveries that create solutions from cells to society. The center conducts basic, clinical, and population research, and is a campus in the LSU System.
The research enterprise at Pennington Biomedical includes over 530 employees within a network of 44 clinics and research laboratories, and 13 highly specialized core service facilities. Its scientists and physician/scientists are supported by research trainees, lab technicians, nurses, dietitians, and other support personnel. Pennington Biomedical is a globally recognized state-of-the-art research institution in Baton Rouge, Louisiana.
Dr. Steven Heymsfield and Dr. Peter Katzmarzyk Rank Among the World’s Most Influential Researcher
December 2nd, 2024
Dr. Steven Heymsfield and Dr. Peter Katzmarzyk of Pennington Biomedical Research Center in Baton Rouge, La. Credit: Pennington Biomedical Research Center
Pennington Biomedical Research Center’s Dr. Steven Heymsfield and Dr. Peter Katzmarzyk are among the most influential researchers in the world who demonstrate significant and broad influence in their fields, according to Clarivate Analytics’ 2024 List of Highly Cited Researchers.
This honor highlights researchers whose work has had significant global influence, as evidenced by their exceptional citation records in leading scientific publications. The 2024 Highly Cited Researchers hail from more than 1,200 institutions in 59 nations and regions.
The Highly Cited Researchers list, compiled annually by Clarivate Analytics, identifies scientists who are among the top 1 percent of researchers in their field, as measured by citations in the Web of Science database during the period from 2013 to 2023.
“Pennington Biomedical is home to all-star researchers known worldwide, and this recognition for Dr. Heymsfield and Dr. Katzmarzyk shows the impact they are having in the field of obesity and nutrition research,” said Dr. John Kirwan, Pennington Biomedical Executive Director. “We congratulate them both for this recognition and all of Louisiana and Baton Rouge can be proud that they are conducting their world-renowned research here at Pennington Biomedical.”
Dr. Heymsfield and Dr. Katzmarzyk are internationally recognized for their groundbreaking contributions to obesity research, physical activity, and public health.
Steven Heymsfield, M.D., Professor of Metabolism & Body Composition, has an h-index of 141. He is listed on 1,314 publications that have been cited close to 80,000 times. His most cited paper, “Epidemiology of sarcopenia among the elderly in New Mexico,” published in the American Journal of Epidemiology, has been cited more than 2,800 times.
“This achievement reflects not just individual recognition, but the incredible support and collaboration of everyone at Pennington Biomedical,” Dr. Heymsfield said. “Conducting impactful and high-quality research requires not only dedication but also access to outstanding facilities, resources, and a thriving scientific community—qualities exemplified at Pennington Biomedical. I am grateful to be part of an institution that fosters innovation and excellence in research, enabling us to address critical challenges in health and nutrition on a global scale.”
Peter Katzmarzyk, Ph.D., Associate Executive Director for Population and Public Health Sciences; Professor; and Marie Edana Corcoran Endowed Chair in Pediatric Obesity and Diabetes, has an h-index of 100. He is listed on 587 publications that have been cited more than 45,000 times. His paper, “Effect of Physical Inactivity on Major Non-Communicable Diseases Worldwide: An Analysis of Burden of Disease and Life Expectancy,” published in Lancet, has been cited more than 5,400 times.
“Being named among the world’s highly cited researchers is both an honor and a reflection of the impact our work is making on global health,” Katzmarzyk said. “This recognition underscores the importance of addressing critical issues like physical inactivity, obesity, and chronic disease to improve lives worldwide.”
The 2024 Highly Cited Researchers list features 3,560 Highly Cited Researcher awards in 20 fields, with an additional 3,326 recognitions for outstanding performance in multiple fields (cross-field).
“The Highly Cited Researchers list identifies and celebrates exceptional individual researchers at Pennington Biomedical whose significant and broad influence in their fields translates to impact in their research community. Their pioneering innovations contribute to a healthier, more sustainable and secure world. These researchers’ achievements strengthen the foundation of excellence and innovation that drives societal progress,” said David Pendlebury, Head of Research Analysis at the Institute for Scientific Information at Clarivate.
About the Pennington Biomedical Research Center
The Pennington Biomedical Research Center is at the forefront of medical discovery as it relates to understanding the triggers of obesity, diabetes, cardiovascular disease, cancer and dementia. Pennington Biomedical has the vision to lead the world in promoting metabolic health and eliminating metabolic disease through scientific discoveries that create solutions from cells to society. The center conducts basic, clinical, and population research, and is a campus in the LSU System.
The research enterprise at Pennington Biomedical includes over 530 employees within a network of 44 clinics and research laboratories, and 13 highly specialized core service facilities. Its scientists and physician/scientists are supported by research trainees, lab technicians, nurses, dietitians, and other support personnel. Pennington Biomedical is a globally recognized state-of-the-art research institution in Baton Rouge, Louisiana.
of Pennington Biomedical Research Center in Baton Rouge, La. Credit: Pennington Biomedical Research Center
Blog of Intellectual Capital 